EICHORPublic-registry site landscape for NCT05686239, “A Study to Evaluate RL-007 in the Treatment of Cognitive Impairment Associated With Schizophrenia (CIAS)”, a Cognitive Impairment Associated With Schizophrenia (CIAS) study sponsored by Recognify Life Sciences. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT05686239 (registry record) |
| Study title | A Study to Evaluate RL-007 in the Treatment of Cognitive Impairment Associated With Schizophrenia (CIAS) |
| Official title | An Adaptive, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of RL-007 in the Treatment of Cognitive Impairment Associated With Schizophrenia (CIAS) |
| Sponsor | Recognify Life Sciences |
| Condition(s) | Cognitive Impairment Associated With Schizophrenia (CIAS); Cognitive Impairment; Schizophrenia |
| Phase | PHASE2 |
| Listed sites | 36 |
| Site countries | United States, Bulgaria, Czechia, Poland |
Patient-friendly overview of this study: eichor.com/study/NCT05686239.
Eichor generates a preliminary site-risk snapshot for NCT05686239 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Cognitive Impairment Associated With Schizophrenia (CIAS) trials
More from Recognify Life Sciences
← Eichor home · All tracked trials · Cognitive Impairment Associated With Schizophrenia (CIAS) studies · Weekly briefs
